OBJECTIVES: T1 mapping by cardiac magnetic resonance imaging (CMR) is able to determine the extracellular volume fraction. Wild-type transthyretin amyloidosis (WT-ATTR) is characterized by extracellular amyloid deposition in the heart. Recent reports indicated a reduction of left ventricular (LV) myocardial mass in WT-ATTR after consumption of epigallocatechin-3-gallate, the main catechin in green tea. It remained unclear, whether reduction of LV myocardial mass reflects decrease of amyloid load or progressive atrophy of cardiomyocytes. METHODS: This study included 7 male patients with CMR repetitively performed before and 12 months after daily consumption of green tea extract (600 mg epigallocatechin-3-gallate). Short axis slices as well as 2-, 3-, and 4-chamber views were acquired using SSFP sequences. T1 mapping was created out of 11 mid-ventricular short axis views with increasing inversion times using a single breath-hold modified look-locker inversion recovery sequence before and 15 min after Gadolinium contrast administration. RESULTS: After 12 months, a significant decrease of LV myocardial mass [198 (160; 212) vs. 180 (142; 204) g; p < 0.05] was observed. Moreover, a significant decrease of native [T1 1110 (1072; 1150) ms vs. 1080 (970; 1101), p < 0.05 or p = 0.03] was noticed. The calculated extracellular volume decreased in 5 patients (62.5%) by 7% and increased in 2 patients (37.5%) by 9.5%, in trend resulting in a (not significant) decrease of median ECV by 2.4%. Left ventricular ejection fraction (LVEF) [57 (48; 65) vs. 55 (47; 64) %; p = 0.3] remained unchanged. CONCLUSIONS: This study provided further evidence of LV myocardial mass reduction in patients with WT-ATTR daily consuming green tea extract. Additionally, this study gave first insights into the histomorphological correlate of LV mass reduction using T1 mapping. LV mass reduction appeared to be rather due to a decrease of amyloid load than atrophy of cardiomyocytes.
OBJECTIVES: T1 mapping by cardiac magnetic resonance imaging (CMR) is able to determine the extracellular volume fraction. Wild-type transthyretin amyloidosis (WT-ATTR) is characterized by extracellular amyloid deposition in the heart. Recent reports indicated a reduction of left ventricular (LV) myocardial mass in WT-ATTR after consumption of epigallocatechin-3-gallate, the main catechin in green tea. It remained unclear, whether reduction of LV myocardial mass reflects decrease of amyloid load or progressive atrophy of cardiomyocytes. METHODS: This study included 7 male patients with CMR repetitively performed before and 12 months after daily consumption of green tea extract (600 mg epigallocatechin-3-gallate). Short axis slices as well as 2-, 3-, and 4-chamber views were acquired using SSFP sequences. T1 mapping was created out of 11 mid-ventricular short axis views with increasing inversion times using a single breath-hold modified look-locker inversion recovery sequence before and 15 min after Gadolinium contrast administration. RESULTS: After 12 months, a significant decrease of LV myocardial mass [198 (160; 212) vs. 180 (142; 204) g; p < 0.05] was observed. Moreover, a significant decrease of native [T1 1110 (1072; 1150) ms vs. 1080 (970; 1101), p < 0.05 or p = 0.03] was noticed. The calculated extracellular volume decreased in 5 patients (62.5%) by 7% and increased in 2 patients (37.5%) by 9.5%, in trend resulting in a (not significant) decrease of median ECV by 2.4%. Left ventricular ejection fraction (LVEF) [57 (48; 65) vs. 55 (47; 64) %; p = 0.3] remained unchanged. CONCLUSIONS: This study provided further evidence of LV myocardial mass reduction in patients with WT-ATTR daily consuming green tea extract. Additionally, this study gave first insights into the histomorphological correlate of LV mass reduction using T1 mapping. LV mass reduction appeared to be rather due to a decrease of amyloid load than atrophy of cardiomyocytes.
Authors: Frederick L Ruberg; Mathew S Maurer; Daniel P Judge; Steven Zeldenrust; Martha Skinner; Antony Y Kim; Rodney H Falk; Kin N Cheung; Ayan R Patel; Arian Pano; Jeffrey Packman; Donna Roy Grogan Journal: Am Heart J Date: 2012-08 Impact factor: 4.749
Authors: Marianna Fontana; Sanjay M Banypersad; Thomas A Treibel; Viviana Maestrini; Daniel M Sado; Steven K White; Silvia Pica; Silvia Castelletti; Stefan K Piechnik; Matthew D Robson; Janet A Gilbertson; Dorota Rowczenio; David F Hutt; Helen J Lachmann; Ashutosh D Wechalekar; Carol J Whelan; Julian D Gillmore; Philip N Hawkins; James C Moon Journal: JACC Cardiovasc Imaging Date: 2014-01-08
Authors: Alicia M Maceira; Sanjay K Prasad; Philip N Hawkins; Michael Roughton; Dudley J Pennell Journal: J Cardiovasc Magn Reson Date: 2008-11-25 Impact factor: 5.364
Authors: Michael Bietenbeck; Anca Florian; Zornitsa Shomanova; Karin Klingel; Ali Yilmaz Journal: Clin Res Cardiol Date: 2017-03-20 Impact factor: 5.460
Authors: Kristina Dahlem; Guido Michels; Carsten Kobe; Alexander C Bunck; Henrik Ten Freyhaus; Roman Pfister Journal: Clin Res Cardiol Date: 2017-03-16 Impact factor: 5.460
Authors: Ulf K Radunski; Gunnar K Lund; Dennis Säring; Sebastian Bohnen; Christian Stehning; Bernhard Schnackenburg; Maxim Avanesov; Enver Tahir; Gerhard Adam; Stefan Blankenberg; Kai Muellerleile Journal: Clin Res Cardiol Date: 2016-07-07 Impact factor: 5.460
Authors: Max Fritschka; Michael Schlegl; Adrian Borges; Mathias Werner; Rolf Gebker; Burkert Pieske; Sebastian Kelle Journal: Clin Res Cardiol Date: 2017-01-23 Impact factor: 5.460
Authors: Maaike van den Boomen; Riemer H J A Slart; Enzo V Hulleman; Rudi A J O Dierckx; Birgitta K Velthuis; Pim van der Harst; David E Sosnovik; Ronald J H Borra; Niek H J Prakken Journal: J Magn Reson Imaging Date: 2017-11-13 Impact factor: 4.813
Authors: Fabian aus dem Siepen; Ralf Bauer; Matthias Aurich; Sebastian J Buss; Henning Steen; Klaus Altland; Hugo A Katus; Arnt V Kristen Journal: Drug Des Devel Ther Date: 2015-12-04 Impact factor: 4.162